- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05920122
Aqueous vs Alcohol Chlorhexidine Skin Preparation for Prevention of Cesarean Section Wound Infections
November 27, 2023 updated by: Yaneve Fonge
A Randomized Control Trial of Chlorhexidine Gluconate Aqueous Solution vs Chlorhexidine Gluconate With Isopropyl Alcohol Skin Preparations for Prevention of Cesarean Section Wound Infections
This will be a single-center randomized control trial comparing the efficacy of two different formulations of Chlorhexidine surgical skin preparation in preventing cesarean section wound infections.
Participants will be randomized to either 4% Chlorhexidine Gluconate aqueous solution (CHG) or 2% Chlorhexidine with isopropyl alcohol (CHG-IPA) 70% to examine the risk of infectious morbidity in those undergoing cesarean delivery.
There will also be a cost-effectiveness analysis of the two preoperative skin preparations.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
1470
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yaneve Fonge, MD
- Phone Number: 412-641-6331
- Email: Fongeyn@upmc.edu
Study Contact Backup
- Name: Carrie Bennett, MD
- Email: bennettcd2@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15260
- Recruiting
- University of Pittsburgh
-
Contact:
- Yaneve N Fonge
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Women undergoing cesarean delivery at Magee Women's Hospital
Exclusion Criteria:
- Inability to obtain consent (language barrier, emergency cesarean section etc.)
- Allergy to chlorhexidine or alcohol
- Chorioamnionitis
- Emergency cesareans where cannot wait for chlorhexidine alcohol to dry
- bowel injury at time of cesarean section
- Women who are delivered at another institution and are transferred postpartum to Magees Women's Hospital
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2% Chlorhexidine gluconate with 70% alcohol (ChloraPrep)
Including cases undergoing elective &non elective caesarean section.
Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area.
The lever will be pinched to activate the ampoule and release the antiseptic.
The solution will be given time to partially load in the sponge.
The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs.
The antiseptic will be given time to dry (3 min)
|
Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area.
The lever will be pinched to activate the ampoule and release the antiseptic.
The solution will be given time to partially load in the sponge.
The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs.
The antiseptic will be given time to dry (3 min)
Other Names:
|
Experimental: 4% chlorhexidine gluconate (Hibiclens)
Including cases undergoing elective & nonelective caesarean section.
Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel.
The area scrubbed will be the same as the chloraprep group.
|
Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel.
The area scrubbed will be the same as the chloraprep group.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Surgical site Infection
Time Frame: Within 30 days post cesarean
|
Superficial or deep surgical-site infection within 30 days after cesarean delivery, on the basis of the National Healthcare Safety Network definitions of the Centers for Disease Control and Prevention.
|
Within 30 days post cesarean
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Endometritis
Time Frame: Within 30 days post cesarean
|
Within 30 days post cesarean
|
|
Number of participants with seroma
Time Frame: Within 30 days post cesarean
|
Within 30 days post cesarean
|
|
Number of Participants With Skin Irritation
Time Frame: within 48 hours from delivery
|
within 48 hours from delivery
|
|
Number of Participants With Allergic Reaction
Time Frame: within 48 hours from delivery
|
within 48 hours from delivery
|
|
Number of Participants with intrabdominal/pelvic abscess
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants with necrotizing fasciitis
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants with sepsis
Time Frame: Within 90 days post cesarean
|
With wound/uterine infection as the source
|
Within 90 days post cesarean
|
Length of Hospital Stay
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants With Re-admissions or Office Visits for Wound-related Problems
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants with ICU admission for wound infectious complications
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants with Need for wound opening, exploration, or washout in the operating room
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants who needed wound vacuum
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of Participants who needed home health
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of patients who needed antibiotics
Time Frame: Within 90 days post cesarean
|
will also collect route of antibiotic administration and duration of treatment to assist with cost analysis
|
Within 90 days post cesarean
|
Number of doses of antibiotic treatment
Time Frame: Within 90 days post cesarean
|
for wound infection complications
|
Within 90 days post cesarean
|
Antibiotic regimens (medication names) used to treat infection
Time Frame: Within 90 days post cesarean
|
for wound infection complications
|
Within 90 days post cesarean
|
Number of participants with positive culture from wound
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
The type of bacterial species isolated from wound infection cultures
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Number of participants with hematoma
Time Frame: Within 90 days post cesarean
|
Within 90 days post cesarean
|
|
Cost Savings
Time Frame: Within 90 days post cesarean
|
costs (dollars) associated with a hospital stay, office visits and re-admissions for infection-related complications, ICU admission for infectious complications, wound exploration or washout in the operating room, wound vacuum use, home health, antibiotic prescriptions, and duration of treatment will be collected and used to calculate the cost of wound infection management.
The cost difference between groups will be calculated to estimate cost savings.
|
Within 90 days post cesarean
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yaneve Fonge, MD, University of Pittsburgh
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Springel EH, Wang XY, Sarfoh VM, Stetzer BP, Weight SA, Mercer BM. A randomized open-label controlled trial of chlorhexidine-alcohol vs povidone-iodine for cesarean antisepsis: the CAPICA trial. Am J Obstet Gynecol. 2017 Oct;217(4):463.e1-463.e8. doi: 10.1016/j.ajog.2017.05.060. Epub 2017 Jun 7.
- Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010 Jan 7;362(1):18-26. doi: 10.1056/NEJMoa0810988.
- Caughey AB, Wood SL, Macones GA, Wrench IJ, Huang J, Norman M, Pettersson K, Fawcett WJ, Shalabi MM, Metcalfe A, Gramlich L, Nelson G, Wilson RD. Guidelines for intraoperative care in cesarean delivery: Enhanced Recovery After Surgery Society Recommendations (Part 2). Am J Obstet Gynecol. 2018 Dec;219(6):533-544. doi: 10.1016/j.ajog.2018.08.006. Epub 2018 Aug 15.
- Zuarez-Easton S, Zafran N, Garmi G, Salim R. Postcesarean wound infection: prevalence, impact, prevention, and management challenges. Int J Womens Health. 2017 Feb 17;9:81-88. doi: 10.2147/IJWH.S98876. eCollection 2017.
- Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, Keohane C, Denham CR, Bates DW. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013 Dec 9-23;173(22):2039-46. doi: 10.1001/jamainternmed.2013.9763.
- Costantine MM, Rahman M, Ghulmiyah L, Byers BD, Longo M, Wen T, Hankins GD, Saade GR. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. Am J Obstet Gynecol. 2008 Sep;199(3):301.e1-6. doi: 10.1016/j.ajog.2008.06.077.
- Saeed KB, Greene RA, Corcoran P, O'Neill SM. Incidence of surgical site infection following caesarean section: a systematic review and meta-analysis protocol. BMJ Open. 2017 Jan 11;7(1):e013037. doi: 10.1136/bmjopen-2016-013037.
- Merkow RP, Ju MH, Chung JW, Hall BL, Cohen ME, Williams MV, Tsai TC, Ko CY, Bilimoria KY. Underlying reasons associated with hospital readmission following surgery in the United States. JAMA. 2015 Feb 3;313(5):483-95. doi: 10.1001/jama.2014.18614.
- Ferrannini E, Santoro D, Manicardi V. The association of essential hypertension and diabetes. Compr Ther. 1989 Nov;15(11):51-8.
- Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A, Liu Z. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev. 2015 Apr 21;2015(4):CD003949. doi: 10.1002/14651858.CD003949.pub4.
- Maiwald M, Chan ES. Pitfalls in evidence assessment: the case of chlorhexidine and alcohol in skin antisepsis. J Antimicrob Chemother. 2014 Aug;69(8):2017-21. doi: 10.1093/jac/dku121. Epub 2014 Apr 28.
- Hadiati DR, Hakimi M, Nurdiati DS, Masuzawa Y, da Silva Lopes K, Ota E. Skin preparation for preventing infection following caesarean section. Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD007462. doi: 10.1002/14651858.CD007462.pub5.
- Levin I, Amer-Alshiek J, Avni A, Lessing JB, Satel A, Almog B. Chlorhexidine and alcohol versus povidone-iodine for antisepsis in gynecological surgery. J Womens Health (Larchmt). 2011 Mar;20(3):321-4. doi: 10.1089/jwh.2010.2391. Epub 2011 Feb 16.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 9, 2023
Primary Completion (Estimated)
October 31, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
June 7, 2023
First Submitted That Met QC Criteria
June 15, 2023
First Posted (Actual)
June 27, 2023
Study Record Updates
Last Update Posted (Actual)
November 29, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY23030049
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Site Infection
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
MinaPharm PharmaceuticalsRecruitingSurgical Site InfectionsEgypt
-
Karolinska University HospitalStockholm South General HospitalRecruitingPostoperative Surgical Site InfectionSweden
-
Washington University School of MedicineCompleted
-
Region SkaneVinnovaCompleted
-
Singapore General HospitalNovem Healthcare Pte LtdTerminatedSuperficial Surgical Site InfectionSingapore
-
Halmstad County HospitalCompleted
-
Population Health Research InstituteActive, not recruitingSurgical Site InfectionsCanada
-
University of RochesterSage Products, Inc.Completed
-
Montefiore Medical CenterCompletedSurgical Site Infection Following Cesarean DeliveryUnited States
Clinical Trials on 2% Chlorhexidine gluconate with 70% alcohol
-
Zurex Pharma, Inc.CompletedSurgical Site InfectionUnited States
-
3MCompletedSurgical Procedure, Unspecified | Surgical Skin PreparationRomania
-
Universidad Complutense de MadridUnknownIngrown ToenailSpain
-
3MCompletedBacterial Reduction on Skin Flora Post-product ApplicationUnited States
-
Zurex Pharma, Inc.Completed
-
Zurex Pharma, Inc.Completed
-
Zurex Pharma, Inc.CompletedSurgical Skin PreparationUnited States
-
Zurex Pharma, Inc.TerminatedSurgical Site InfectionUnited States
-
3MCompletedBacterial Reduction Post-product ApplicationUnited States
-
Zurex Pharma, Inc.Completed